Defining the next generation in clinical Oncology treatments

The war on cancer continues to rage on and whilst great steps forward have been made, demand continues to skyrocket with long waiting lists, ever ageing populations and the ongoing development of lifestyle-related disease. Advances in diagnostics, coupled with AI and huge investment into research and clinical trials has yielded great results enabling precise and personalised treatments, particularly in the fields of DNA and Immunotherapy. To counter rising costs and increase outcomes, health systems are focussing on prevention and early diagnosis. This session brings technology, provision and therapy perspectives on the next decade of cancer care. It addresses how organisations partner with each other, payors and regulators to speed up access and drive quality. It explores how to scale whilst containing costs.